Clinical trials: Hydroxychloroquine
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Hepatocellular Cancer
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…
- Trial name
- NCT03037437
- Testing
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID-19, Cancer
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer.
- Trial name
- NCT04381988
- Testing
- Hydroxychloroquine, Radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
RA
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants.
- Trial name
- SARIL-RA-EASY (NCT02057250)
- Testing
- Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS)
- Where
- 53 sites in United States, Chile and 4 more
- Volunteers
- 217 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis
The study has been designed as a 48-week, double-blind, randomized, controlled study comparing the use of leflunomide alone to combinations of leflunomide-sulfasalazine-HCQ, and methotrexate-sulfasalazine-HCQ.
- Trial name
- NCT00579878
- Testing
- Leflunomide, Methotrexate-Sulfasalazine-Hydroxychloroquine, Leflunomide-Sulfasalazine-Hydroxychloroquine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Nebraska
Coronavirus, Corona Virus Infection
PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and prophylaxis/treatment in health care workers because…
- Trial name
- NCT04353037
- Testing
- Group 1 HCQ
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- UnitedHealth Group
Hepatitis C
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C
Proof-of Concept, Open-Label, Two-Stage Study without Direct Individual Benefit The proposed study design consists of two treatment periods and one treatment arm.
- Trial name
- NCT01833845
- Testing
- Ribavirin, Hydroxychloroquine
- Where
- 2 sites in France
- Volunteers
- 4 people
- Sponsor
- BioLineRx, Ltd.
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04527549
- Testing
- Dabrafenib mesylate, Hydroxychloroquine, Trametinib dimethyl sulfoxide
- Where
- 199 sites in United States
- Volunteers
- 5 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating patients with estrogen receptor positive, HER2 negative breast…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03774472
- Testing
- Hydroxychloroquine, Letrozole, Palbociclib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
SARS-CoV Infection, Covid19
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus.
- Trial name
- TriACT (NCT04605588)
- Testing
- Nitazoxanide, Ribavirin, Hydroxychloroquine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19
Treating COVID-19 With Hydroxychloroquine (TEACH)
Treatments for COVID-19 are urgently needed. Hydroxychloroquine (HCQ) is an antimalarial and immunomodulatory agent being repurposed for COVID-19 therapy based off in vitro data suggesting a possible antiviral effect.
- Trial name
- NCT04369742
- Testing
- Hydroxychloroquine (HCQ)
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- NYU Langone Health
Sarcoma
A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
Determine the objective response rate in sarcoma patients treated with hydroxychloroquine and sirolimus.
- Trial name
- NCT01842594
- Testing
- Sirolimus and hydroxychloroquine
- Where
- Taiwan
- Volunteers
- 13 people
- Sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
Systemic Lupus Erythematosus, SLE
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.
- Trial name
- ALE06 (NCT01946880)
- Testing
- Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 102 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Tumor
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Baseline levels of PAR-4 secreted by normal cells are generally inadequate to cause massive apoptosis in cancer cells and drugs that bolster the secretion of PAR-4 would constitute an important therapeutic advance.The apoptosis…
- Trial name
- NCT02232243
- Testing
- Hydroxychloroquine, 200mg twice dailiy, Hydroxychloroquine, 400mg twice daily
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Peng Wang, MD PhD
Individuals Undergoing Cardiac and General Surgery
Hydroxychloroquine and Cognitive Function After Surgery
The purpose of this study is to determine whether hydroxychloroquine decreases the relative leakage of the brain barrier after surgery.
- Trial name
- NCT03025087
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Pre-diabetes
Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology…
- Trial name
- NCT01326533
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pittsburgh
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine.
- Conditions
- Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01649947
- Testing
- Paclitaxel, Carboplatin, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rutgers, The State University of New Jersey
Rheumatoid Arthritis, Insulin Resistance
Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis
The purpose of this study is to determine whether hydroxychloroquine (HCQ) reduces insulin resistance in non-diabetic subjects with rheumatoid arthritis (RA).
- Trial name
- RA PLUS (NCT01132118)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Gastrointestinal Cancer
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
This research study is for patients with an advanced cancer that carries a mutation in a gene called KRAS. Genes are parts of our DNA which carry instructions for a cell (the smallest component of an body part).
- Trial name
- MEKiAUTO (NCT04214418)
- Testing
- Cobimetinib, Hydroxychloroquine, Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Columbia University